Development of XXXX during lung transplantation follow-up.

@entity1 @entity5
OBJECTIVE: Lung transplant @entity1 survival has significantly improved over the last 2 decades, which has resulted in an increased incidence of @entity5 . We undertook a descriptive, retrospective study of our series of transplant @entity1 . @entity1 AND METHODS: The study included 129 transplantations from 1999 to 2006. Ten @entity1 (7.75%) developed 11 @entity5 processes during the follow-up period. RESULTS: In these 10 @entity1 with neoformative processes (group 1), 40% were male and 60% female, compared with 62% male and 38% female in the @entity5 -free group (group 2). The overall mean age was 50.5 +/- 15.4 years in group 1 and 48 +/- 14 years in group 2. The @entity5 were: lymphomas (2) and @entity5 in the urinary tract (2), colon (2), kidney (1), skin (2), breast (1), and native lung (1). The median time from organ transplantation to diagnosis was 21 +/- 16 months. Of the 10 @entity1 in group 1, 60% died, within a median of 9 months after diagnosis. Treatment consisted of surgery in 4 @entity1 , chemotherapy in 5, and chemoradiotherapy in 1. The immunosuppression was changed after @entity5 diagnosis in 30% of the @entity1 . CONCLUSIONS: Pharmacological immunomodulation caused a higher incidence of @entity5 , in addition to a worse prognosis for these diseases, which demonstrated the importance of adjusting the dose and searching for adequate therapeutic combinations.
